JP2008524165A - インドリノン及びその抗増殖薬としての使用 - Google Patents

インドリノン及びその抗増殖薬としての使用 Download PDF

Info

Publication number
JP2008524165A
JP2008524165A JP2007546068A JP2007546068A JP2008524165A JP 2008524165 A JP2008524165 A JP 2008524165A JP 2007546068 A JP2007546068 A JP 2007546068A JP 2007546068 A JP2007546068 A JP 2007546068A JP 2008524165 A JP2008524165 A JP 2008524165A
Authority
JP
Japan
Prior art keywords
group
formula
heteroalicyclic
hydrogen
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007546068A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008524165A5 (enExample
Inventor
ダリル マコーネル
ツェルニロフスキー ウルリケ ヴァイアー
マリア インパニャティエロ
シュテフェン シュトイラー
ラルフ ブリュックナー
ベルント クリシュト
ボードー ベーツェマイアー
フランク ヒルベルク
アルミン ヘッケル
ゲラルト ユールゲン ロート
ヨルグ クライ
リンツ トルシュテン レーマン
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2008524165A publication Critical patent/JP2008524165A/ja
Publication of JP2008524165A5 publication Critical patent/JP2008524165A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
JP2007546068A 2004-12-17 2005-12-15 インドリノン及びその抗増殖薬としての使用 Pending JP2008524165A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04029981 2004-12-17
PCT/EP2005/056821 WO2006064044A1 (en) 2004-12-17 2005-12-15 Indolinones and their use as antiproliferative agents

Publications (2)

Publication Number Publication Date
JP2008524165A true JP2008524165A (ja) 2008-07-10
JP2008524165A5 JP2008524165A5 (enExample) 2009-02-12

Family

ID=34927830

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007546068A Pending JP2008524165A (ja) 2004-12-17 2005-12-15 インドリノン及びその抗増殖薬としての使用

Country Status (5)

Country Link
US (2) US20060135592A1 (enExample)
EP (1) EP1828123A1 (enExample)
JP (1) JP2008524165A (enExample)
CA (1) CA2589501A1 (enExample)
WO (1) WO2006064044A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023523051A (ja) * 2020-04-23 2023-06-01 ▲復▼旦大学 脂質代謝関連疾患の予防又は治療用化合物

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759383B2 (en) 2005-02-22 2010-07-20 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
TWI333959B (en) * 2005-08-31 2010-12-01 Academia Sinica Methods and reagents for the analysis and purification of polysaccharides
CN102491932A (zh) * 2011-12-26 2012-06-13 天津科技大学 一种3-吲哚啉酮类衍生物及其制备方法及其应用
JP6378308B2 (ja) * 2013-03-13 2018-08-22 ボストン バイオメディカル， インコーポレイテッド がんの処置のための、がん幹細胞経路キナーゼの阻害剤としての３−（アリールまたはヘテロアリール）メチレンインドリン−２−オン誘導体
US9745253B2 (en) 2015-03-13 2017-08-29 Forma Therapeutics, Inc. Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
CN106854173A (zh) * 2016-12-23 2017-06-16 山东轩德医药科技有限公司 一种2‑羰基吲哚酮‑6‑羧酸甲酯的制备方法
CN122295328A (zh) * 2023-12-05 2026-06-26 先正达农作物保护股份公司 除草衍生物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1115640A (zh) * 1994-07-26 1996-01-31 中国医学科学院血液学研究所 3-取代芳基氧化吲哚类化合物的应用
WO1996040116A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Indolinone compounds for the treatment of disease
WO2000056709A1 (en) * 1999-03-24 2000-09-28 Sugen, Inc. Indolinone compounds as kinase inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689806B1 (en) * 1999-03-24 2004-02-10 Sugen, Inc. Indolinone compounds as kinase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1115640A (zh) * 1994-07-26 1996-01-31 中国医学科学院血液学研究所 3-取代芳基氧化吲哚类化合物的应用
WO1996040116A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Indolinone compounds for the treatment of disease
US5883116A (en) * 1995-06-07 1999-03-16 Sugen, Inc. 3-(2'-alkoxybenzylidenyl)-2-indolinone and analogues thereof for the treatment of disease
WO2000056709A1 (en) * 1999-03-24 2000-09-28 Sugen, Inc. Indolinone compounds as kinase inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023523051A (ja) * 2020-04-23 2023-06-01 ▲復▼旦大学 脂質代謝関連疾患の予防又は治療用化合物
JP7744689B2 (ja) 2020-04-23 2025-09-26 ▲復▼旦大学 脂質代謝関連疾患の予防又は治療用化合物

Also Published As

Publication number Publication date
US20060135592A1 (en) 2006-06-22
CA2589501A1 (en) 2006-06-22
EP1828123A1 (en) 2007-09-05
US20070088051A1 (en) 2007-04-19
WO2006064044A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
JP5010917B2 (ja) ｃ−Ｋｉｔ調節因子および使用方法
TW202325284A (zh) N-環丙基吡啶并[4,3-d]嘧啶-4-胺衍生物及其用途
TWI433677B (zh) 雜環化合物及其用途
CN102459187B (zh) Janus激酶抑制化合物和方法
CN110546145B (zh) 一种氮杂芳基衍生物、其制备方法和在药学上的应用
CN105503827B (zh) Egfr抑制剂及其制备方法和用途
JP2009511557A (ja) 癌の処置のためのピリミジン誘導体
CN117659051A (zh) Kras g12d蛋白抑制剂和其用途
JP2008505855A (ja) Ｐｌｋインヒビターとしてのピリミジン化合物
BRPI0720635A2 (pt) Compostos orgânicos e seus usos
JP6096673B2 (ja) ピラゾリルグアニジンｆ１ｆ０−ａｔｐアーゼ阻害剤およびその治療的使用
CN107176933B (zh) 一种含氮烷基化和芳基化亚砜亚胺的吲哚胺-2,3-双加氧酶抑制剂
EP1678168A2 (en) P70s6 kinase modulators and method of use
CN103582643A (zh) 蛋白激酶抑制剂
JP2012153720A (ja) ピラゾールキナーゼモジュレーターおよび使用方法
JP2021191753A (ja) 疾患の処置のための複素環化合物
WO2020062883A1 (zh) 基于知母菝契皂苷元结构的衍生物、药物组合物及其应用
WO2017023899A1 (en) Inhibitors of ack1/tnk2 tyrosine kinase
AU2021261856B2 (en) Small molecule regulators of steroid receptor coactivators and methods of use thereof
EP1644338A1 (en) 2, 4, 6-trisubstituted pyrimidine derivatives useful for the treatment of neoplastic and autoimmune diseases
JP2005526764A (ja) ピリミジン化合物
WO2006064044A1 (en) Indolinones and their use as antiproliferative agents
CN103002899A (zh) 作为pi3k抑制剂用于治疗抗增殖障碍的哌嗪子基三嗪化合物
JP7407309B2 (ja) Ｃｓｆ－１ｒ阻害剤としての置換｛５－メトキシ－６－［（５－メトキシピリジン－２－イル）メトキシ］ピリジン－３－イル｝メチル化合物
WO2023109751A1 (zh) 嘧啶或吡啶类衍生物及其医药用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120319

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120820